- June 20, 2019 Kowa Pharmaceuticals America, Inc. Receives Pediatric Indication and Six-Month Pediatric Exclusivity for LIVALO® (pitavastatin)
- January 28, 2019 Kowa Pharmaceuticals America, Inc. Enters into Co-Promotion Agreement with Allergan for BYSTOLIC® (nebivolol) in the United States
- January 9, 2019 Kowa Pharmaceuticals America, Inc. Announces Appeals Court Decision Upholding Patent Protection for LIVALO® (pitavastatin)
- May 8, 2018 Actor and Comedian Howie Mandel Joins Take Cholesterol to Heart, a National Education Campaign from Kowa Pharmaceuticals America, Inc.
- February 5, 2018 Kowa Pharmaceuticals America, Inc. Announces Agreement with Apotex to Resolve All Outstanding Litigation Related to LIVALO® (pitavastatin)
- April 19, 2017 Kowa Pharmaceuticals America, Inc. Announces INTREPID Trial Results in The Lancet HIV Showing Superior LDL Cholesterol Reduction with LIVALO® (pitavastatin) Compared with Pravastatin in Adults with HIV and Dyslipidemia
- October 3, 2017 TV Icon and Heart Disease Survivor Regis Philbin Joins Kowa Pharmaceuticals America, Inc. to Launch National Education Campaign "Take Cholesterol to Heart"
- October 11, 2017 Kowa Pharmaceuticals America, Inc. Announces Court Decision to Uphold Patent Protection for LIVALO® (pitavastatin calcium)
- May 4, 2015 New Meta-Analysis on Pitavastatin Demonstrates No Adverse Effect Compared with Placebo or Other Statins
- March 31, 2014 Amarin and Kowa Pharmaceuticals America, Inc. Announce U.S. Co-Promotion Agreement for Vascepa® (icosapent ethyl) Capsules
- April 2, 2014 NFL MVP Kurt Warner And Wife Brenda Tackle A Public Health Issue Affecting Millions Of Americans With National Cholesterol Awareness Campaign
- October 28, 2014 Landmark Trial To Explore The Prevention Of Heart Disease In People Living With HIV
- March 7, 2013 New Superiority Trial Showed LIVALO® (pitavastatin) 4 mg Provided Significantly Greater LDL-C Reduction in HIV-Infected Adults with Dyslipidemia versus Pravastatin 40 mg
- February 13, 2012 New Study Data Published Assessing the Effect of LIVALO® vs. Crestor® on International Normalized Ratio on Steady-State Warfarin
- May 31, 2012 New Data Showed LIVALO® (pitavastatin) Met Primary Endpoint of LDL-C Reduction When Compared with Pravastatin
- June 19, 2012 John O’Hurley Teams up with the National Lipid Association, Kowa Pharmaceuticals America, Inc. and Eli Lilly and Company to Announce Results of Landmark Statin USAGE Survey, Largest Known Survey of Cholesterol Patients
- July 22, 2012 Pharmacokinetic Study Results Released Evaluating Interactions Between LIVALO® (pitavastatin) and Protease Inhibitor Combination (darunavir/ritonavir) in Healthy Volunteers
- November 5, 2012 Results from the Largest Known Cholesterol Survey Conducted in the U.S. Announced at the American Heart Association’s Annual Scientific Sessions
- July 18, 2011 New Data Showed Minimal Potential for Drug Interaction between Cholesterol Drug LIVALO® and a Common Antiretroviral Therapy
- June 21, 2010 Kowa Pharmaceuticals America and Lilly Announce U.S. Availability of Livalo
- December 23, 2009 Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
- December 14, 2009 Kowa Pharmaceuticals America Announces the Divestment of Cambia and PRO-571
- August 3, 2009 FDA Approves LIVALO® for Primary Hypercholesterolemia and Combined Dyslipidemia
- June 22, 2009 FDA Approves Cambia™ for Migraine
- April 14, 2009 Kowa Pharmaceuticals America Announces Strategic Divestiture of Diclofenac Assets
